Eton Pharmaceuticals Q2 2024 GAAP EPS $(0.12) Misses $(0.07) Estimate, Sales $9.074M Beat $8.800M Estimate
Portfolio Pulse from Benzinga Newsdesk
Eton Pharmaceuticals (NASDAQ:ETON) reported Q2 2024 GAAP EPS of $(0.12), missing the $(0.07) estimate by 71.43%. However, sales of $9.074M beat the $8.800M estimate by 3.11%, despite a 24.36% decrease from the same period last year.
August 08, 2024 | 9:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eton Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.12), missing the $(0.07) estimate by 71.43%. Sales of $9.074M beat the $8.800M estimate by 3.11%, but were down 24.36% YoY.
The significant EPS miss is likely to negatively impact the stock price in the short term, despite the sales beat. The YoY sales decline adds to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100